Skip to content
Menu

UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5.5

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $5 to $5.5.

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $5 to $5.5.

Read at benzinga.com